Compound class:
Synthetic organic
Comment: LY3405105 is a clinical stage kinase inhibitor. It inhibits the activity of CDK7 and is being investigated for anti-tumour potential [2]. The chemical structure is one of those claimed in Eli Lilly's patent WO2019099298A1 [1]. The absolute stereochemistry of LY3405105 is unclear. Sava et al. (2020) present the structure without specified stereochemistry [2]. We show the (3S) enantiomer, which is Example 1 in the patent as this was the most potent CDK7 inhibitor, and it was the example that was tested for in vitro and in vivo anti-proliferative activity..
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
(3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl 4-{[5-methyl-3-(propan-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl]amino}piperidine-1-carboxylate |
Database Links | |
GtoPdb PubChem SID | 440816725 |
PubChem CID | 138608760 |
Search Google for chemical match using the InChIKey | GRDAHPJRLCTJNA-BXKJMJEDSA-N |
Search Google for chemicals with the same backbone | GRDAHPJRLCTJNA |
UniChem Compound Search for chemical match using the InChIKey | GRDAHPJRLCTJNA-BXKJMJEDSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | GRDAHPJRLCTJNA-BXKJMJEDSA-N |